CD274 and cancer: Three anti-PD-L1 MAbs have been approved so far for anti-cancer treatment, one IgG1 (avelumab, Fc competent) and 2 IgG1 mutated (atezolizumab and durvalumab, Fc silent) (Table 2) [110,111,112,113].